Evaluation of patient satisfaction after botulinum toxin A injection for the management of masticatory myofascial pain and dysfunction - A pilot study

Cranio. 2021 Jan;39(1):12-16. doi: 10.1080/08869634.2018.1562660. Epub 2019 Jan 2.

Abstract

Objective: To evaluate patient satisfaction with botulinum toxin type A injections for the management of masticatory myofascial pain and dysfunction. Methods: The study group included 25 patients with myofascial pain and dysfunction. Maximum mouth opening (MMO), measured with a ruler, and pain, measured on a 10-cm visual analog scale (VAS), were assessed before treatment and six weeks after treatment. Satisfaction with the treatment, measured on a 10-cm VAS, was obtained six weeks post-treatment. Results: The mean satisfaction score six weeks post-injection was 6.74/10, with a significant improvement in both MMO and pain. Satisfaction was positively correlated with a decrease in pain. Discussion: Botulinum toxin type A injections were well tolerated for the treatment of masticatory myofascial pain and dysfunction in patients with temporomandibular disorder. Improvements were observed in both MMO and pain, with most patients satisfied with the management of pain.

Keywords: Myofascial pain; TMD; VAS; botulinum toxin; maximum mouth opening; pain management; patient satisfaction.

MeSH terms

  • Botulinum Toxins, Type A*
  • Humans
  • Injections, Intramuscular
  • Neuromuscular Agents*
  • Pain
  • Patient Satisfaction
  • Pilot Projects
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A